Use of Inhibitors of Scinderin and/or Ephrin-A1 for Treating Tumors
AssigneeInstitut Gustave Roussy
InventorSalem Chouaib
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of inhibitors of the expression or the activity of scinderin and/or of ephrin-A1 inhibitors for increasing the susceptibility of tumor cells to CTL killing. Such inhibitors may be for instance interfering RNAs targeting the scinderin gene and/or interfering RNAs targeting the ephrin-A1 gene.
Claims5
A method of increasing the susceptibility of a tumor target cell to cytolytic T lymphocytes (CTL) killing comprising administering to the tumor target cell a composition wherein the composition comprises of an inhibitor of the expression or the activity of scinderin and/or of an inhibitor of the expression or the activity of ephrin-A1.
A pharmaceutical composition comprising an interfering RNA targeting the scinderin gene or a DNA precursor of said interfering RNA, and an interfering RNA targeting the ephrin-A1 gene or a DNA precursor of said interfering RNA.
Dependencies are inferred from the claim text.